CAR-T Cells
A variety of CAR constructs are available in second-or third-generation formats to fit any researcher’s preference. Constructs with secondary tags (GFP, Flag, TF) are also available.
A variety of CAR constructs are available in second-or third-generation formats to fit any researcher’s preference. Constructs with secondary tags (GFP, Flag, TF) are also available.
Promab Biotechnologies has generated CARs (chimeric
antigen receptors) specific
for a variety of target antigens, many of which are overexpressed on tumour cells.
These target antigens include CD19, CD22, CD133, Her-2, EGFR, Mesothelin, and
more.
In addition, Promab has modified the CARs in several ways to increase their utility,
including adding inducible caspase-9 as a safety switch; adding non-immunogenic
tags to provide for CAR identification and selection; and using different costimulatory
domains to modulate CAR functional responses.
Promab Biotechnologies uses high-tier lentivirus transduction to introduce the CARs
into T cells, generating CAR-T cells. Promab has also generated CAR-NK cells and
CAR-macrophages for a subset of CARs. The CAR-T cells are validated using
multiple methods, including flow cytometry (to determine the CAR-T frequency and
phenotype), real-time and end-point cytotoxicity assays, cytokine production and
checkpoint protein upregulation.
For a negative control, Promab has generated a mock CAR which lacks the target-
recognizing scFv domain but can be detected with the Beam-2 antibody. Promab
also offers non-transduced T cells as another negative control.
For more information on CAR-T Cells, click on more
info.
For more information on CAR-T Custom Service, click
here.